Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treat...
June 21 2021 - 7:00AM
(NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on
gene-modified cellular and immune therapies in infectious diseases
and cancer, today announced that the company has acquired an
exclusive license for an innovative technology to potentially treat
and prevent all variants of coronavirus, including the cause of
COVID-19, as well as influenza. A request for a Pre-Investigator
New Drug meeting for the COVID-19 treatment will be submitted to
the FDA in the near term.
The novel approach, developed by Dr. Serhat
Gumrukçu, tricks the viruses to trigger the cells it infects to
commit suicide instead of becoming a virus-making factory. The
technology is delivered by a nanoparticle, allowing it to either
rapidly treat an infection or to wait in ambush for a cell to
become infected to prevent (prophylaxis, similar to taking drugs to
protect from becoming infected with malaria or HIV) future
infections. Because target cells of the viruses live up to 20
months in human airways, it is possible that a single inhalation
could both rapidly treat and protect against infection for
relatively long periods of time. The part of the virus that is
tricked is similar in all variants of SARS-CoV-2 as well as other
coronaviruses that cause disease in humans, including approximately
20 percent of common colds. In addition, all pandemic influenza
viruses since 1918 have a similar region as that targeted by this
technology.
Dr. Mark Dybul, a prominent expert in HIV and
Executive Vice Chairperson of the Board of Enochian BioSciences,
said, “The current COVID-19 variants are concerning. With the slow
rollout of vaccines globally, there is a high risk of new mutations
that will entirely escape the effectiveness of current vaccines. In
addition, there are no currently available treatments that are easy
to use and treat all variants. This novel technology potentially
offers hope to help stop this pandemic as well as to prevent future
coronavirus and influenza pandemics.”
Dr. Gumrukçu is a co-founder and inventor of
Enochian BioSciences, and Director of Seraph Research Institute
(SRI). He previously presented the initial SARS-CoV-2 findings at
two prestigious scientific conferences. In March 2021, the
SARS-CoV-2 data was presented at the Conference on Retroviruses and
Opportunistic infections, and in 2020, the influenza data was
presented at the Conference of the American Society of Gene and
Cell Therapy. Presentations can be found at:
https://www.enochianbio.com/investors-media/events-and-presentations/.
About Enochian BioSciences,
Inc.Enochian BioSciences, Inc. is a biopharmaceutical
company dedicated to identifying, developing, manufacturing, and
commercializing gene-modified cell therapy. The company’s
gene-modified cell therapy platform can be applied to multiple
indications, including HIV/AIDS and Oncology. For more information,
please visit Enochianbio.com
About Seraph Research Institute
(SRI)Seraph Research Institute is a Los Angeles-based
non-profit research institution, which runs basic science,
translational and clinical research in pursuit of cures and
effective treatments for chronic viral infections, cancers, and
genetic disorders. For more information, please visit
Seraphinstitute.org
Forward-Looking
StatementsStatements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties,
including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are
forward-looking statements, which can be identified by the use of
forward-looking terminology such as “believes,” “plans,” “expects,”
“aims,” “intends,” “potential,” or similar expressions. Actual
events or results may differ materially from those projected in any
of such statements due to various uncertainties, including as set
forth in Enochian BioSciences’ most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement, and Enochian
BioSciences undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date
hereof.
Contact: ir@enochianbio.com
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Sep 2023 to Sep 2024